News / New publications

Research

We work together for a better translational approach, from basic to clinical science

  • Read more

Core facilities

Our advanced core facilities offer excellent opportunities

  • Read more

Recruitment

We welcome the best research talents from Norway and the rest of the world

  • Read more

Archives IEMR

  • Publications
  • News archive
  • Visual profile

About IEMR

  • About
  • Funding
  • Collaborations
  • Staff

Contact IEMR

  • Contact
  • Group leaders
  • Leadership
  • Safety representative (VO)

A potential anti-fibrotic role for ADAMTSL2 in heart failure

Karoline B. Rypdal, Pugazendhi M. Erusappan, A. Olav Melleby, Deborah E. Seifert, Sheryl Palmero, Mari E. Strand, Theis Tønnessen, Christen P. Dahl, Vibeke Almaas, Dirk Hubmacher, Suneel S. Apte, Geir Christensen & Ida G. Lunde 

The extracellular matrix glycoprotein ADAMTSL2 is increased in heart failure and inhibits TGFβ signalling in cardiac fibroblasts

—

 

TGFβ-signalling is a major driver of pathological fibrosis, which accompanies most heart disease. Targeting TGFβ therapeutically has proven difficult due to its pleiotropic role in the body, and thus, strategies to target specific TGFβ pathways are warranted to develop new treatment for cardiac fibrosis. Together with colleagues, PhD student Karoline Rypdal in the group of Ida Lunde, found that the extracellular matrix protein, ADAMTSL2, was increased in failing hearts of patients and mice. By over-expressing ADAMTSL2 in cultures of cardiac fibroblasts, they discovered that ADAMTSL2 inhibited TGFβ-signalling and had an anti-fibrotic effect on cardiac fibroblast phenotype, preventing the fibroblasts from transdifferentiating into pro-fibrotic myofibroblasts. These findings indicate a potential novel target for preventing pathological TGFβ-signalling in heart failure.

https://www.nature.com/articles/s41598-021-99032-2

Karoline Bjarnesdatter Rypdal

Postdoctoral fellow

  • View profile

Ida Gjervold Lunde

Researcher

  • View profile

Institute for Experimental Medical Research

Oslo University Hospital, Ullevål

PB 4956 Nydalen

NO-0424 Oslo

Norway

  • Research
  • Core facilities
  • Recruitment
  • Publications
  • News archive
  • Visual profile
  • About
  • Funding
  • Collaborations
  • Staff
  • Contact
  • Group leaders
  • Leadership
  • Safety representative (VO)